Black Friday online shopping grew more than 21 percent amid the pandemic


Goldman Sachs: These 3 shares can exceed 40%

Expectations of good news in the near future will give a boost to markets. Last month, both the S&P 500 and NASDAQ were 11% higher than the new record high. Investors are looking forward to the COVID vaccine coming out before winter. And the election results, with Democrat Joe Biden taking the presidency while Republicans appear stronger in Congress, promise to avoid extremism typical of a divided government. In short, investors are looking forward to a “return to normal” environment in the coming months. And that makes them look for for-profit stocks. In light of this, Goldman Sachs analysts are hitting the table on three stocks in particular, noting that each could rise above 40% next year. After running both ticks through the TipRanks database, we learned that the rest of the Street is also right in the bull camp. Codiack BioSciences (CDAK) As we all learned from the coronavirus epidemic, some new things in medicine are having a huge impact on our world. Codiack aims to translate this principle into good. The goal of this research-oriented drug formulation is to transform exosome therapies into a whole new group of drugs. Exosomes are the mechanism of RNA breakdown and are able to carry genetic material around the body. And that is the potential. Codiack has developed a design platform for designing exosomal proteins capable of carrying and protecting drug molecules across the cell wall. In fact, proteins mimic the pathways used by viruses, but are not viral and are designed to carry a “payload” of therapeutic agents. Successfully, exosome therapy offers doctors to design a drug that delivers specific agents to certain cells to combat a particular disease. Kodiack is involved in all aspects of exosome therapies, from design to manufacturing, and currently has a total of seven active ingredients – during discovery, preclinical testing, and the start of first-phase trials. In the life sciences, success or failure is about both this pipeline and its diversified, active assemblies in the new biotechnology sector. in the field of pharmaceuticals, Codiack is a great resource for attracting investors. To attract these investors, the company went public last October, selling 5.5 million shares at an opening price of $ 14.10 per share. Fans of the health name include Graig Suvannavejh, an analyst at Goldman Sachs. The analyst wrote: “There has long been an interest in exosomes in the Biopharma industry, but the development of special functions and large-scale production are both challenging. Of the multi-competitor field, CDAK has made the most significant progress on both sides and, as such, we consider their technology platform to be the best in their category. “” As stock performance has been low since the IPO (-37%), we find risk / reward at the current level very convincing and with key 2021 datasets to ensure potential risk-free and positive stock inflection, “the analyst concluded. CDAK is valued by a Buy, and its $ 29 price target shows its level of confidence – an increase of 222% over the next year. (Click here to view Suvannavejh’s history) Buy was rated 3 reviewers in the first half of 2007. The stock price is $ 8.90 and the average price target of $ 24 represents a one-year upside potential of 166% (See CDAK Stock Analysis at TipRanks.) Arcutis Biotherapeutics (ARQT) Acrutis A pioneer in the treatment of dermatological diseases, Arcutis is involved in the discovery of the next generation of dermatological treatments – an important gap especially when you realize that one common disease, psoriasis, has not seen FDA approval for a new treatment for more than two decades. The company takes advantage of the latest developments in immunology. and inflammation to find new approaches to treating the skin. The goal is to facilitate the combined treatment of patients and physicians such as psoriasis, alopecia, atopic dermatitis, seborrheic dermatitis, and vitiligo, to name a few. The company’s leading candidate, ARQ-151 (roflumilast cream) is approx. to enter a phase 3 study of atopic dermatitis and is in advanced phase 3 in plaque psoriasis. Arcutis recently released an update on the positive results of its Phase 2 trials of ARQ-151 in atopic dermatitis. The drug is a once-a-day treatment, and patients have significantly relieved their symptoms, especially itching and sleep-related sleep problems. This is another stock in the Suvannavejh coverage universe. The Goldman analyst is impressed with the developments in the company’s pipeline work, noting: “ARQT has provided updated information on the outcome of its Phase 2 end-of-date meetings with the FDA following ARQ-151 in atopic dermatitis (AtD). Feedback from regulators has been widely encouraging, especially given the robust long-term safety data generated by ARQT for ARQ-151 in plaque psoriasis … ”Accordingly, Suvannavejh buys ARQT and sets a $ 36 price target that is 40 indicates space. % upward growth in 2021. (Click here to view Suvannavejh’s history) Arcutis 2 gave a recently purchased review, so the consensus rating is Moderate Buy. The average price target for the stock is $ 37, an increase of 44% from the current level. (See ARQT Stock Analysis at TipRanks) Oak Street Health (OSH) With the latest set, we are moving from medical research to medical care. Specifically, Oak Street Health is the operator of a primary care clinic and is part of the Medicare network. The company operates and has clinics in Illinois, Indiana, Michigan, Pennsylvania and Ohio, as well as New York, North Carolina, Rhode Island, Tennessee and Texas. It has been in operation for eight years and was listed last summer, holding a listing in August. In the third quarter, when the company operated primarily as a listed entity, OSH generated revenue of $ 217.9 million. Revenue increased 56% year-over-year. Earnings per share met expectations of 15 cents. The company’s expansion is advancing at a rapid pace, and in October, Oak Street moved to New York with the opening of its 70th place in Brooklyn. The planned Texas expansion, which includes a partnership with Walmart, is also progressing as planned, and Oak Street has opened its first Walmart community clinic in the Dallas-Fort Worth area of ​​Carrollton. Robert Jones, who covers this stock of Goldman, set $ 74. price target to support Buy’s rating. Currently, this target represents an increase of ~ 58% over the next 12 months. (Click here to view Jones history) “The results suggest that operations are still on track, with few incremental updates since the 2Q call, where management noticed a resumption of headquarters openings, (reversed) marketing efforts, and personal visits. COVID. In 3Q, OSH opened 13 new centers and will reach 73-75 by the end of the year … The company maintained that it continues to operate at a high level in locations with high COVID cases, such as Chicago and Detroit, ”Jones remarked. Overall, Strong Buy analysts ’consensus OSH rating is based on 8 ratings, 7 purchases, and only one withholding. The stock is selling for $ 46.94 and its average price target of $ 61.29 suggests an increase of ~ 31% for next year. (See OSH’s stock analysis on TipRanks.) If you want to find good ideas for attractive value trading in health stocks, visit TipRanks Best Buyable Shares, a newly introduced tool that combines all of TipRanks ’stock information. exclusively to senior analysts. The content is used for informational purposes only. It is very important that you do your own analysis before you start investing.